Problematic lesions in cirrhosis
Alessandro Furlan, Amir A. Borhani – 28 February 2018
Problematic lesions in cirrhosis
Alessandro Furlan, Amir A. Borhani – 28 February 2018
Role of alcohol in nonalcoholic steatohepatitis: Rush university (Con) patients with nonalcoholic steatohepatitis should be abstinent from alcohol use
Maham Lodhi, Jaimin Amin, Sheila Eswaran – 28 February 2018
Use of the CRISPR/Cas9‐based epigenetic gene activation system In Vivo: A new potential therapeutic modality
Samar H. Ibrahim, Keith D. Robertson – 28 February 2018
Pro: Moderate alcohol use is beneficial in nonalcoholic steatohepatitis
Scott McHenry, Saad Alghamdi, Mauricio Lisker‐Melman – 28 February 2018
Think global, act local: Responsibility for the liver transplant candidate
Peter L. Abt, Kim M. Olthoff – 28 February 2018
Clinical Liver Disease: Introducing hot topics in hepatology
Lisa B. VanWagner, Nancy Reau – 28 February 2018
Hepatic diagnostics in pregnancy: Biopsy, biomarkers, and beyond
Michael A. Heneghan, Mary D. Cannon – 27 February 2018
Daclatasvir and sofosbuvir treatment of decompensated liver disease or post‐liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real‐world cohort
Paul Kwo, Michael W. Fried, K. Rajender Reddy, Consuelo Soldevila‐Pico, Saro Khemichian, Jama Darling, Phillippe J. Zamor, Andrew A. Napoli, Beatrice Anduze‐Faris, Robert S. Brown – 27 February 2018 – We report the findings of an early access program providing treatment for chronic hepatitis C virus infection (any genotype) with daclatasvir and sofosbuvir with/without ribavirin to patients with Child‐Pugh class C cirrhosis or prior liver transplant recipients with recurrent hepatitis C virus infection and advanced fibrosis/cirrhosis.
Glycogen storage disease type Ia: Adult presentation with microcytic anemia and liver adenomas
Wouter Moest, Wendy van der Deure, Ted Koster, Marcela Spee‐Dropková, Linda Swart‐Busscher, Robbert J. de Haas, Terry G.J. Derks – 27 February 2018